Olivia Calder
About Olivia Calder
Olivia Calder is a Research Associate at Bristol Myers Squibb with a background in biochemistry from Northeastern University and experience in pharmacology at Sanofi Genzyme.
Company
Olivia Calder is currently a Research Associate at Bristol Myers Squibb. She is engaged in research and development activities within the organization, contributing her expertise to various projects. Her work includes setting up and optimizing degradation assays to evaluate PROTAC activity in human and murine cell lines using automated westerns and HTRF assays. Olivia also engages in the generation of custom cell lines and the optimization of virus production protocols.
Title
As a Research Associate, Olivia Calder plays an integral role in conducting and supporting scientific research. Her responsibilities involve creating and optimizing assays, generating and maintaining cell lines, and performing transient transfections to explore protein functions. She contributes significantly to the research initiatives and supports the various projects through her technical expertise.
Education and Expertise
Olivia Calder studied at Northeastern University from 2016 to 2021, achieving a Bachelor of Science (B.S.) degree in Biochemistry. Her academic background in biochemistry has facilitated her ability to perform specialized tasks within her roles, such as generating custom cell lines and optimizing assay protocols. Olivia's technical skills extend to setting up degradation assays, optimizing virus production, and performing endpoint and kinetic HIBIT assays.
Background
Prior to her role at Bristol Myers Squibb, Olivia Calder worked at Sanofi Genzyme as a Rare Genetic Disease Pharmacology Co-Op in 2018 for five months. During her tenure, she would have gained practical experience contributing to her skill set in pharmacology and research. Her background includes managing research tasks such as isolation of primary immune and non-immune cells from murine samples and studying in-vivo and ex-vivo degradation processes.
Research Projects and Initiatives
Olivia Calder has been involved in several technical projects. She set up and optimized degradation assays for PROTAC activity, generated around 30 custom cell lines via stable lentiviral transduction, and optimized virus production protocols for higher lentiviral titers. Additionally, she performed transient transfections using DNA plasmids and conducted endpoint and kinetic HIBIT assays to study protein homeostasis. Olivia has also isolated primary cells from murine samples to study the degradation of lead PROTAC molecules in-vivo and ex-vivo, and actively maintains multiple mammalian cell lines for project and assay support.